Abstract 3611
Background
Androgen deprivation therapy (ADT) is standard treatment for rising PSA with/without circulating tumor cells (CTCs) but adverse events (AEs) limit patient acceptance. We report results of SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) in combination with a CYP3A4 inducer, mTOR inhibitor and catalyst that does not lower testosterone (T).
Methods
Phase 2 with a rising PSA (per PCWG3), no disease on imaging and detectable CTCs.
Results
From Sept 2016-April 2019, 35 subjects consented; 23 evaluable (completed >1 cycle); 60.9% were post RT. Mean age 70.6; BMI 28.9; 21.7% black. Mean T rose (319.1 to 346.0 ng/dL p = 0.08) over 12 weeks. Subjects did not report side effects commonly associated with hormone suppression. Assessments of EORTC measured domains sexual health, overall health, and quality of life remained stable, with depression, hot flushes, and enlarged breast reported as “Not at all” (remained at 1). There was no detectable worsening in any domain of EORTC QLQ-C30 or QLQ-PR25. No clinically significant changes were seen in weight, hct, glu, urinary N telopeptide, MAP (in normotensives and hypertensives), heart rate, Ca ++, LDH, bsAlkPhos, triglycerides, albumin, or QTc. NLR decreased at the end of cycle 1 in 75% of those with radiographic and/or PSA progression vs 53% of those who did not. 15/23 (65.2%) subjects reported experiencing an AE. 1 unrelated Grade 3; 18/35 (51.4%) at least possibly related to drug. No AEs were related to T levels. There were no skeletal or cardiovascular events. From initial diagnosis of PSA rise 100% (23/23) remained metastases free. PSA declined (4% 1/23) stabilized (83% 19/23) or rose (13% 3/23). 56.5% (13/23) subjects experienced an improvement in median PSA DT. Median DT time improved from 6.2 to 8.0 months for all subjects completing 3 cycles of therapy. CTCs were > 5 in 100% at baseline. After 12 weeks, there was a 65.3% (-100% to -8.8%) median CTC decrease from baseline (n = 18), with all subjects having CTC counts below baseline and 2 undetectable.
Conclusions
SM-88 may delay the start of HT and be useful when normal T is preferred. QOL was maintained without ADT AEs. Favorable effects on PSA and CTCs kinetics were observed consistent with a favorable treatment effect. Trials to confirm these benefits are planned.
Clinical trial identification
NCT02796898.
Editorial acknowledgement
Legal entity responsible for the study
Tyme Inc.
Funding
Tyme Inc.
Disclosure
G. Del Priore: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Tyme Inc. G.H. Sokol: Advisory / Consultancy: Tyme Inc. A. Vandell: Full / Part-time employment: Tyme Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract